# THE EVOLUTION OF ANTI-RETROVIRAL THERAPY IN NIGERIA

O.S. Michael

Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Nigeria

Correspondence

## Dr. O.S. Michael,

Dept. of Pharmacology and Therapeutics University of Ibadan

Nigeria

E-mail: micobaro@yahoo.com

## **SUMMARY**

This historical review examines developments in anti-retroviral therapy research over the years. International milestones in the treatment of HIV from 1984 to 2011 are described. Using results of a PUBMED literature search, the evolution of HIV therapy in Nigeria is examined. Areas of research highlighted are the Monitoring of ART, adherence to ART, and highly active anti-retroviral therapy in Nigeria. From the first report on the PUBMED search by Akanmu *et al* from Lagos in 2001 to reports in 2013, it is undeniable that HIV scientists in Nigeria have produced a good number of very informative and relevant results in the area of anti-retroviral therapy research in Nigeria.

Key words: Medical History, Anti-retroviral therapy, HAART, Nigeria

## INTRODUCTION

HIV/AIDS not only represents the most severe epidemic in modern times, but also the greatest public health challenge in history<sup>1</sup>. Nigeria, the most populous country in Africa, has continued to be a reference point of evaluation of progress within the continent. Often referred to as the giant of Africa, there is little doubt that we do have giant challenges, one of which is the scourge of HIV-AIDS. The National Agency for the Control of AIDS (NACA) estimated that as at 2010, 3.1 million Nigerian were living with the virus and that the annual HIV positive birth was 56,681. The agency also estimated that every year about 281,180 new infections occur and, about 1,512,720 people living with HIV required Anti-Retroviral Therapy.

Highly Active Antiretroviral Therapy (HAART) remains the single most significant advance in the field of HIV research. The Clinical Pharmacology of drugs used in the treatment of the virus has undergone rapid evolution over the years. In 1983 the virus was simultaneously identified and isolated by two research teams led by Luc Montagnier and Robert Gallo. Following the isolation of the virus, efforts aimed at developing a diagnostic antibody test yielded positive results. The isolation of the virus and diagnostic test led to the development of methods of screening of agents that could inhibit or eliminated the virus from infected individuals.

The first agent that showed promise in vitro was Zidovudine (AZT) and in 1987 the drug was tried in humans for the first time. The use of the drug resulted in improvement of the survival of HIV infected individuals and, very remarkably, the reduction of

mother to child transmission. However, the drug had significant side effects as a result of which efforts at identifying more anti-retroviral agents were intensified. Not long after, three other Nucleoside Reverse



Luc Montagnier

Transcriptase inhibitors (NRTIs), zalcitabine (ddC), didanosine (ddI) and stavudine (d4T), were tried and approved for use in HIV-1 infection. Within a couple of years the well known groups of anti-retroviral agents were approved for the treatment of HIV-1 in humans (Fig 1).

The next significant milestone in the evolution of ART was the use of drug combinations of agents which proved to be many times more effective than single agents<sup>3,4</sup>. Although initial trials resulted in an increase in toxicity, combination therapy was found to be more




Fig 1: Antiretroviral drugs approved for use in humans<sup>2</sup>.

effective and led to delay in the development of drug resistance. With careful selection, and the use of agents in different anti-retroviral groups, toxicity could be reduced. Very rapidly, highly active anti-retroviral therapies (HAART), which are different combinations of different groups of ART in a triple regimen, were formulated. This development remains the most significant milestone in HIV research. The "decade of HAART" began with the 11th International Conference on AIDS in Vancouver, British Columbia, July 7-16, 1996. Two publications by Hammer and others in 1996 and 19973,4 precipitated other studies that provided undeniable evidence in support of the use of combination therapy in the treatment of HIV-AIDS; the foundation studies that gave birth to the era of HAART.

Today, international and national guidelines and policies of management of HIV are based on HAART. HAART significantly slows down the progress of the virus and diseases in infected humans. The regimen has turned HIV infection from an inevitably fatal condition into a chronic manageable disease, however, in resource limited countries challenges with anti-retroviral therapy include problems with adherence, availability, cost, attitudes towards the disease, monitoring of viral loads, assessment of plasma or other body fluid drug levels, monitoring of CD4 counts, and drug toxicity.

# Milestones in the Development of Anti-Retroviral Therapy (ART)

From the discovery and approval of AZT to the present, the treatment of HIV has undergone significant changes. Every milestone has led to improvements in treatment outcome. The development of protease inhibitors, the possibility of reducing mother-child transmission of the virus, discovery of latently infected long-lived HIV cellular reservoirs, preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load, approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir), and Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines are very significant milestones (table 1)¹.

## ART Research in Nigeria

At this point we shall examine key researches that have documented the progress and evolution of ART in Nigeria. The evolution of ARTs in Nigeria as documented in this historical review was put together after a PUBMED search conducted on 30<sup>th</sup> November, 2013, using EndNotes<sup>TM</sup> software version7.0. The search was done using the terms antiretroviral therapy [title] AND Nigeria [any field]. Retrieved manuscripts were evaluated by the author and relevant abstract were summarized appropriately to fit into the scope of this review. Only a small

**Table 1:** Milestones in the development of ART

A system for rapid testing of agents with activity against HIV was established at the National Cancer Institute, NIII, USA Zidovudnic (AZT), a nucleoside HIV reverse transcriptase inhibitor (NRTI) was proven active against murine leukernia vitus at Burroughs-Wellcome laboratories.  NCI/NIII proves that AZT suppresses HIV replication in-vitro. AZT phase I trial start  1986 Phase II trial of AZT stopped by DSMB because patients treated with AZT had a significant higher survival than the placebo (1 death in 145 vs. 19 deaths in 137 AZT approved by US FIDA First description of the mechanism of HIV resistance to AZT  1987 AZT approved by US FIDA First description of the mechanism of HIV resistance to AZT  1998 Resists of phase III trials of AZT in mildly symptomatic individuals and in persons with less than 500 CD4+cells 1992 Introduction of other NRTIs didanosine (ddl), zalcitabine (ddC) and stavoudine (d41) 1993 Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival  (Concorde trial results presented at the Berlin AIDS Conference). First phase I/II trials of HIV proteose inhibitors (PIS) presented in Berlin 1994 Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected morbers.  1995 Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials).  Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease.  Better understanding of HIV pathogenesis rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.  Discovery of laterally infected long-lived HIV cellular reservoirs.  US FIDA approval of two new drug classes: protease inhibitors (NINKII) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 055 and BroAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker f	Voor	Milestone
NIH, USA Zidovudine (AZI), a nucleoside IIIV reverse transcriptase inhibitor (NRTI) was proven active against murine leukemia vitus as Burroughs-Wellcome laboratories.  NIJ/NIH proves that AZI suppresses HIV replication in vitro.  AZI plause I rial start  Plasse II trial of AZI stopped by DSMB because patients treated with AZI had a significant higher survival than the placebo (I death in 145 vs. 19 deaths in 137  Bay I rial start  AZI approved by US IDA  Results of phase III trials of AZI in mildly symptomatic individuals and in persons with less than 500 CD4+ cells  Introduction of other NRTIEs didanosine (ddl), zalcitabine (ddC) and stavudine (ddT)  Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival  Concorde trial results presented at the Berlin AIDS Conference).  First phase I/II trials of AZI in mildly symptomatic individuals and in persons with less than 500 CD4+ cells  Concorde trial results presented at the Berlin AIDS Conference).  First phase I/II trials of HIV protease inhibitors (Pls) presented in Berlin  Pomonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of IIIV-infected mothers.  Better understanding of HIV pathogenesis: napid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.  Discovery of latendy infected long-lived HIV cellular reservoirs.  Preliminary positive results of trials using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  Preliminary positive results of trials using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  Preliminary positiv	Year 1984	
<ul> <li>Zidovedine (AZT), a medeoside HIV reverse transcriptase inhibitor (NRTI) was proven active against murine leukemia virus at Burcuphs-Wellcome laboratories.</li> <li>NCL/NIH proves that AZT suppresses HIV replication in-vitro.</li> <li>AZT phase I trail start</li> <li>Phase I trail of AZT stopped by DSMB because patients treated with AZT had a significant higher survival than the placebo (I death in 145 vs. 19 deaths in 137</li> <li>AZT approved by USE FDA</li> <li>Pirst description of the mechanism of HIV resistance to AZT</li> <li>Pirst description of the mechanism of HIV resistance to AZT</li> <li>Pomore and the placebo (I death in 145 vs. 19 deaths in 137</li> <li>AZT approved by USE FDA</li> <li>Pirst description of the mechanism of HIV resistance to AZT</li> <li>Pomore and the placebo of the placebook of the mechanism of HIV suppressate in the placebook of HIV protease inhibitors (PIs) presented in Bedin</li> <li>Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.</li> <li>Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease.</li> <li>Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.</li> <li>Discovery of Istarthy infected long-lived HIV cellular reservoirs.</li> <li>US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, intonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcripase inhibitor (NNRTI) (neciropine).</li> <li>Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Mrx. 035 and BNCAs trials).</li> <li>IAS-USA recommendations suggesting using triple drug combinations, with sustained decrease in pla</li></ul>	1707	
leukemia vinus at Burroughs-Wellcome laboratories.  NEINHH proves that AZT suppresses HIV replication in-vitro.  AZT phase I trial of AZT stopped by DSMB because patients treated with AZT had a significant higher survival than the placebo (I death in 145 vs. 19 deaths in 137  AZT approved by US FDA  Results of phase III trials of AZT in mildly symptomatic individuals and in persons with less than 500 CD4+ cells  Introduction of other NRT1s didanosine (ddI), adictabine (ddC) and stavudine (ddI)  Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival  (Concorde' trial results presented at the Berlin AIDS Conference).  First phase I/II trials of HIV protease inhibitors (PIs) presented in Berlin  Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mother.  Bouble nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials). Demonstration that quantity of IIIV-RNA in plasma predicts progression of the disease.  Better understanding of IIIV pathogenesis: apid viral turnover and mechanisms of IIIV resistance to anti-retroviral drugs.  Discovery of latently infected long-lived HIV cellular reservoirs.  US DA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).  Prelimitary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 053 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.		
NCI/NIH proves that AZT suppresses HIV replication in-vitro. AZT phase I trial tot AZT stopped by DSMB because patients treated with AZT had a significant higher survival than the placebs (I death in 145 vs. 19 deaths in 137 AZT approved by US FDA First description of the mechanism of HIV resistance to AZT Page 1998 Rustis of phase III rails of AZT in middly symptomatic individuals and in persons with less than 500 CD4+cells 1992 Introduction of other NRTIs: didanosine (iddl), zalcitabine (iddC) and stavudine (id41) Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival (Concorde 'rail results presented at the Berlin AIDS Conference). First phase I/III trials of HIV protesse inhibitors (Pls) presented in Berlin Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers. Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials). Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease. Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs. Discovery of latently infected long-lived HIV cellular reservoirs. US FDA approval of two new drug classes: protease inhibitors (Pls) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine). Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials). IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for effecacy presented during the Vancouver AIDS Conference. New nucleoside analog approved (lamivudine, 3TC). First single-tablet combination of two drugs (lamivudine and zidovudine) Pranta decline in morbidity and morbatiny with the introduction of triple combination anti-retroviral therapy. Approval of first		
than the placebo (I death in 145 vs. 19 deaths in 137  AZT approved by US FDA  First description of the mechanism of HIV resistance to AZT  Pages of the third of the placebo (I death in 145 vs. 19 deaths in 137  AZT approved by US FDA  First description of the mechanism of HIV resistance to AZT  Pisst description of the mechanism of HIV resistance to AZT  Resists of phase III trials of AZT in middly symptomatic individuals and in persons with less than 500 CD4+cclls  Introduction of other NRTIs didanosine (ddI), zalcitabine (ddC) and stavudine (d4T)  Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival  (Concorde trial results presented at the Berlin AIDS Conference).  First phase I/II trials of HIV protease inhibitors (PIs) presented in Berlin  Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.  Proposition of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.  Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.  Demonstration that quantity of HIV-cellular reservoirs.  US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).  Preliminary positive results of trials using triple due combinations, with sustained decrease in plasma HIV viral load (Merek to35 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New non-nucleoside reverse transcriptase inhibitor approved (effavirenz)  First single-tablet combination of two drugs (annivudine and zidovudine).  Dramate decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an arti	1985	
than the placebo (I death in 145 vs. 19 deaths in 137  AZT approved by US FDA  Pirst description of the mechanism of HIV resistance to AZT  Results of phase III trials of AZT in mildly symptomatic individuals and in persons with less than 500 CD4+ cells  Introduction of other NRTIs: didanosine (ddl), zalcitabine (ddC) and stavualine (d4T)  Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival  (Concorde' trial results presented at the Berlin AIDS Conference).  First phase I/II trials of HIV protease inhibitors (PIs) presented in Berlin  Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials).  Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.  Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials).  Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease.  Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.  Discovery of latently infected long-lived HIV cellular reservoirs.  ISDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (famivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Darmatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy.  Approval of a second-generation protease inhibitor approved (favirenz)  First de		
<ul> <li>AZT approved by US FDA</li> <li>Pist description of the mechanism of HIV resistance to AZT</li> <li>Results of phase III trials of AZT in mildly symptomatic individuals and in persons with less than 500 CD4+ cells</li> <li>Introduction of other NRTIs: didanosine (ddl), zalcitabine (ddC) and stavudine (d4T)</li> <li>Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival</li> <li>(Concorde' trial results presented at the Berlin AIDS Conference).</li> <li>First phase I/II trials of HIV protease inhibitors (Pls) presented in Berlin</li> <li>Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.</li> <li>Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.</li> <li>Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.</li> <li>Discovery of latently infected long-lived HIV cellular reservoirs.</li> <li>US FDA approval of two new drug classes protease inhibitors (Pls) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).</li> <li>Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 05 and INCAS trials).</li> <li>IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.</li> <li>New non-nucloside reverse transcriptase inhibitor approved (feavierne).</li> <li>First single-tablet combination of two drugs (lamivadine, 3TG).</li> <li>First single-tablet combination of rwo drugs (lamivadine) and a plasma decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy.</li> <li>Appro</li></ul>	1986	
<ul> <li>First description of the mechanism of HIV resistance to AZT</li> <li>Results of phase III trials of AZT in mildly symptomatic individuals and in persons with less than 500 CD4+ cells</li> <li>Introduction of other NRTIs: didanosine (ddI), zalcitabine (ddC) and stavudine (d4T)</li> <li>Domonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival</li> <li>(Concorde' trial results presented at the Berlin AIDS Conference).</li> <li>First phase I/II trials of HIV protease inhibitors (PIs) presented in Berlin</li> <li>Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.</li> <li>Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials).</li> <li>Demonstration of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.</li> <li>Discovery of latently infected long-lived HIV cellular reservoirs.</li> <li>US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapme).</li> <li>Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).</li> <li>IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.</li> <li>New nucleoside analog approved (lamivudine, 3TC).</li> <li>First single-tablet combination of two drugs (lamivudine and zidovudine).</li> <li>Dismatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.</li> <li>New non-nucleoside reverse transcriptase inhibitor approved (enfavirence)</li></ul>		
<ul> <li>Results of phase III trials of AZT in mildly symptomatic individuals and in persons with less than 500 CD4+ cells</li> <li>Introduction of other NRTIs didanosine (ddl), zalcitabine (ddC) and stavudine (d4T)</li> <li>Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival</li> <li>(*Concorde' trial results presented at the Berlin AIDS Conference). First phase I/II trials of IIIV protease inhibitors (PIs) presented in Berlin</li> <li>Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of IIIV-infected mothers.</li> <li>Debug neucloside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials). Demonstration that quantity of IIIV-RNA in plasma predicts progression of the disease.</li> <li>Better understanding of HIV pathogenesis rapid viral tumover and mechanisms of HIV resistance to anti-retroviral drugs.</li> <li>Discovery of latently infected long-lived HIV cellular reservoirs.</li> <li>ISDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine). Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).</li> <li>IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.</li> <li>New nucleoside analog approved (lamivudine, 3TC). First single-tablet combination of two drugs (lamivudine and zidovudine).</li> <li>Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.</li> <li>New non-nucleoside reverse transcriptase inhibitor approved (feavirenz)</li> <li>First descriptio</li></ul>		
cells  Introduction of other NRTIs: didanosine (ddl), zalcitabine (ddC) and stavudine (d4T)  Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival  (Concorde' trial results presented at the Berlin AIDS Conference).  First phase I/II trials of HIV protease inhibitors (Pls) presented in Berlin  Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.  Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials).  Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease.  Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.  Discovery of latently infected long-lived HIV cellular reservoirs.  1986  US IPDA approval of two new drug classes: protease inhibitors (Pls) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and DNCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (devirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a rescond-generation protease inhibitor approved.  (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other Pls will follow in subsequent years at apramacokine boosting		
Introduction of other NRTIs: didanosine (ddl), zalcitabine (ddC) and stavudine (d4T)   Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival   (*Concorde' trial results presented at the Berlin AIDS Conference).   First phase I/II trials of IIIV protease inhibitors (PIs) presented in Berlin   Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.   Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials). Demonstration that quantity of IIIV-RNA in plasma predicts progression of the disease.   Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.   Discovery of latently infected long-lived HIV cellular reservoirs.   US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).   Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).   IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.   New nucleoside analog approved (lamivudine, 3TC).	1990	
Demonstration of the short-lived beneficial effects of nucleoside monotherapy and of no long-term effect on survival  (*Concorde' trial results presented at the Berlin AIDS Conference).  First phase I/II trials of HIV protease inhibitors (PIs) presented in Berlin  Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.  Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials).  Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease.  Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.  Discovery of latently infected long-lived HIV cellular reservoirs.  US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  Private successive analog approved (annivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (effavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor approved (effavirenz)  Approval of an as pharmacolineic boosting.  Measure of the impact of incomplete alherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enf	1000	
survival  (Concorde' trial results presented at the Berlin AIDS Conference).  First phase I/II trials of HIV protease inhibitors (PIs) presented in Berlin  Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.  Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials). Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease.  Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.  Discovery of latently infected long-lived HIV cellular reservoirs.  US FDA approval of two new drug classes: protease inhibitors (PIs) (saguinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NRTI) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (effavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/itonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years atzanavir, 2003, fosamprenavir, 2003, fipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy a		
(*Concorde' trial results presented at the Berlin AIDS Conference).  First phase I/II trials of HIV protease inhibitors (PIs) presented in Berlin  Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.  Dobble nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials). Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease.  Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.  Discovery of latently infected long-lived HIV cellular reservoirs.  Discovery of latently infected long-lived HIV cellular reservoirs.  US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Pramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinari/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacolinetic boosting	1993	
First phase I/II trials of HIV protease inhibitors (PIs) presented in Berlin Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.  Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials). Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease. Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs. Discovery of latently infected long-lived HIV cellular reservoirs.  US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine). Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merek 035 and INCAS trials). LAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC). First single-tablet combination of two drugs (lamivudine and zidovudine).  Parmatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine. New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy. Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, ipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic fai		
<ul> <li>Demonstration of the possibility to reduce mother-to-child transmission through anti-retroviral treatment of HIV-infected mothers.</li> <li>Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials). Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease. Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.</li> <li>Discovery of latently infected long-lived HIV cellular reservoirs.</li> <li>SPA paproval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).</li> <li>Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).</li> <li>IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.</li> <li>New nucleoside analog approved (lamivudine, 3TC).</li> <li>First single-tablet combination of two drugs (lamivudine and zidovudine).</li> <li>Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.</li> <li>New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)</li> <li>First description of metabolic toxicities of anti-retroviral therapy.</li> <li>Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years atzanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.</li> <li>Measure of the impact of incomplete adherence to therapy and of the corr</li></ul>		
HIV-infected mothers.  Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials). Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease. Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti-retroviral drugs.  Discovery of latently infected long-lived HIV cellular reservoirs.  US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NRKTI) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (amivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atzanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  Prist fusion inhibitor approved (enfuvirtide, T20).  Approval of first integrase inhibitor (raltegravie).  Approval of first integrase inhibitor (raltegravie).  Approval of o	1994	
Double nucleoside combinations proven more efficacious over monotherapy (ACTG 175 and Delta trials). Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease.  Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti- retroviral drugs.  Discovery of latently infected long-lived HIV cellular reservoirs.  US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Pramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamperavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuvritide, T20).  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first entry in	1777	
Demonstration that quantity of HIV-RNA in plasma predicts progression of the disease.  Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti- retroviral drugs.  Discovery of latently infected long-lived HIV cellular reservoirs.  1996 US FDA approval of two new drug classes: protease inhibitor (NNRIT) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Prist single-tablet combination of two drugs (lamivudine and zidovudine).  Prist single-tablet ombination of two drugs (lamivudine and zidovudine).  Prist description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopimavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  Pirst fusion inhibitor approved (enfuvirtide, T20).  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first single-tablet combination of three drugs from two classes (ef	1995	
Better understanding of HIV pathogenesis: rapid viral turnover and mechanisms of HIV resistance to anti- retroviral drugs.  Discovery of latently infected long-lived HIV cellular reservoirs.  US FDA approval of two new drug classes: protease inhibitors (Pls) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  Pirst fusion inhibitor approved (enfuviride, T20).  Approval of first integrase inhibitor (altegravir).  Approval of first integrase inhibitor (altegravir).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Prist description of the possibility of obtaining durable HIV suppres		
Discovery of latently infected long-lived HIV cellular reservoirs.  US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosampernavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuvirtide, T20).  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first integrase inhibitor (raltegravir).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of the possibility of obtaining durable HIV		
<ul> <li>US FDA approval of two new drug classes: protease inhibitors (PIs) (saquinavir, ritonavir, indinavir, nelfinavir) and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).</li> <li>Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).</li> <li>IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.</li> <li>New nucleoside analog approved (lamivudine, 3TC).</li> <li>First single-tablet combination of two drugs (lamivudine and zidovudine).</li> <li>Demantic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.</li> <li>New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)</li> <li>First description of metabolic toxicities of anti-retroviral therapy.</li> <li>Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.</li> <li>Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.</li> <li>First fusion inhibitor approved (enfuvirtide, T20).</li> <li>Approval of entricitabine (FTC).</li> <li>First fusion inhibitor approved (enfuvirtide, T20).</li> <li>Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir) Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).</li> <li>Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).</li> <li>Approval of a new NNRTI (etravirine)</li></ul>		retroviral drugs.
and of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine).  Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuvirtide, T20).  Approval of institute proved (enfuvirtide, T20).  Approval of irst single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first integrase inhibitor (raltegravir).  Approval of irst integrase inhibitor (raltegr		Discovery of latently infected long-lived HIV cellular reservoirs.
Preliminary positive results of trials using triple drug combinations, with sustained decrease in plasma HIV viral load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuviritide, T20).  Approval of emtricitabine (FTC).  First fusion inhibitor approved (enfuviritide, T20).  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir) Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir) Approval of first integrase inhibitor (raltegravir).  Approval of first integrase inhibitor (raltegravir).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with mu	1996	
load (Merck 035 and INCAS trials).  IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuvirtide, T20).  Approval of entricitabine (FTC).  First 'nucleotide' reverse transcriptase inhibitor approved (tenofovir).  Single tablet combination of entricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, entricitabine, tenofovir) Approval of first integrase inhibitor (raltegravir).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures.  First description of the increase of non-AIDS-defining events in patients on long term anti-retrovira		
IAS-USA recommendations suggesting using triple therapy and plasma HIV RNA levels as surrogate marker for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC). First single-tablet combination of two drugs (lamivudine and zidovudine).  1998 Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine. New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy. Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuvirtide, T20). Approval of emtricitabine (FTC). First rucleotide' reverse transcriptase inhibitor approved (tenofovir). Single tablet combination of emtricitabine and tenofovir approved. Approval of first integrase inhibitor (raltegravir). Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of anew NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy. Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.		
for efficacy presented during the Vancouver AIDS Conference.  New nucleoside analog approved (lamivudine, 3TC).  First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  2003 First fusion inhibitor approved (enfuvirtide, T20).  Approval of entricitabine (FTC).  First fusion inhibitor approved (enfuvirtide, T20).  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation		
<ul> <li>New nucleoside analog approved (lamivudine, 3TC).         First single-tablet combination of two drugs (lamivudine and zidovudine).         Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.         New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)         First description of metabolic toxicities of anti-retroviral therapy.         Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.         Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.         First fusion inhibitor approved (enfuvirtide, T20).         Approval of emtricitabine (FTC).         First incleotide' reverse transcriptase inhibitor approved (tenofovir).         Single tablet combination of emtricitabine and tenofovir approved.         Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)         Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).         Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.         Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.         First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.         Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.</li></ul>		
First single-tablet combination of two drugs (lamivudine and zidovudine).  Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine.  New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuviride, T20).  Approval of emtricitabine (FTC).  First 'nucleotide' reverse transcriptase inhibitor approved (tenofovir).  Single tablet combination of emtricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first integrase inhibitor (raltegravir).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of e	1007	
<ul> <li>Dramatic decline in morbidity and mortality with the introduction of triple combination anti-retroviral therapy shown in an article published by the New England Journal of Medicine. New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)</li> <li>First description of metabolic toxicities of anti-retroviral therapy. Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting. Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.</li> <li>First fusion inhibitor approved (enfuvirtide, T20). Approval of entricitabine (FTC).</li> <li>First fusion inhibitor approved (tenofovir). Single tablet combination of emtricitabine and tenofovir approved.</li> <li>Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir) Approval of first integrase inhibitor (raltegravir). Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc). Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures. Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures.</li> <li>First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.</li> <li>Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging. Treatment simplification and class sparing strategies addressed in randomized trials.</li> <li>Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the int</li></ul>	1997	
shown in an article published by the New England Journal of Medicine. New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  Pirst fusion inhibitor approved (enfuvirtide, T20). Approval of emtricitabine (FTC).  Approval of emtricitabine (FTC).  Single tablet combination of emtricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first integrase inhibitor (raltegravir).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.	1998	
New non-nucleoside reverse transcriptase inhibitor approved (efavirenz)  First description of metabolic toxicities of anti-retroviral therapy. Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuvirtide, T20). Approval of emtricitabine (FTC).  Single tablet combination of entricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first integrase inhibitor (raltegravir). Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.	1770	
First description of metabolic toxicities of anti-retroviral therapy.  Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuvirtide, T20).  Approval of emtricitabine (FTC).  Single tablet combination of entricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first integrase inhibitor (raltegravir).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.		
Approval of a second-generation protease inhibitor and low-dose ritonavir in a single capsule (lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuvirtide, T20).  Approval of emtricitabine (FTC).  First 'nucleotide' reverse transcriptase inhibitor approved (tenofovir).  Single tablet combination of emtricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first integrase inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.	2000	
subsequent years: atazanavir, 2003, fosamprenavir, 2003, tipranavir, 2005, darunavir, 2006, all to be used with low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  2003 First fusion inhibitor approved (enfuvirtide, T20).  Approval of emtricitabine (FTC).  2004 First 'nucleotide' reverse transcriptase inhibitor approved (tenofovir).  Single tablet combination of emtricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  2009 Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.		
low-dose ritonavir as a pharmacokinetic boosting.  Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  2003 First fusion inhibitor approved (enfuvirtide, T20).  Approval of emtricitabine (FTC).  2004 First 'nucleotide' reverse transcriptase inhibitor approved (tenofovir).  Single tablet combination of emtricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  2009 Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.		(lopinavir/ritonavir) which changed 'salvage treatment' of patients (approval of other PIs will follow in
Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV suppression and risk of therapeutic failure.  2003 First fusion inhibitor approved (enfuvirtide, T20). Approval of emtricitabine (FTC).  2004 First 'nucleotide' reverse transcriptase inhibitor approved (tenofovir). Single tablet combination of emtricitabine and tenofovir approved.  2006 Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  2007 Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  2008 Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  2009 Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  2009 First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  2009 Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  2010 Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.		
suppression and risk of therapeutic failure.  First fusion inhibitor approved (enfuvirtide, T20). Approval of emtricitabine (FTC).  First 'nucleotide' reverse transcriptase inhibitor approved (tenofovir). Single tablet combination of emtricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first integrase inhibitor (raltegravir). Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs. First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging. Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.		
<ul> <li>First fusion inhibitor approved (enfuvirtide, T20).         Approval of emtricitabine (FTC).     </li> <li>First 'nucleotide' reverse transcriptase inhibitor approved (tenofovir).         Single tablet combination of emtricitabine and tenofovir approved.     </li> <li>Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)</li> <li>Approval of first integrase inhibitor (raltegravir).         Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).     </li> <li>Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.         Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.         First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.     </li> <li>Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.         Treatment simplification and class sparing strategies addressed in randomized trials.     </li> <li>Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.</li> </ul>		Measure of the impact of incomplete adherence to therapy and of the correlation between incomplete HIV
Approval of emtricitabine (FTC).  First 'nucleotide' reverse transcriptase inhibitor approved (tenofovir). Single tablet combination of emtricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first integrase inhibitor (raltegravir). Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.	2002	
<ul> <li>First 'nucleotide' reverse transcriptase inhibitor approved (tenofovir).         Single tablet combination of emtricitabine and tenofovir approved.         2006 Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)         2007 Approval of first integrase inhibitor (raltegravir).</li></ul>	2003	
Single tablet combination of emtricitabine and tenofovir approved.  Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)  Approval of first integrase inhibitor (raltegravir).  Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.	2004	
<ul> <li>Approval of first single-tablet combination of three drugs from two classes (efavirenz, emtricitabine, tenofovir)</li> <li>Approval of first integrase inhibitor (raltegravir).         Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).     </li> <li>Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.         Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.         First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.     </li> <li>Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.         Treatment simplification and class sparing strategies addressed in randomized trials.     </li> <li>Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.</li> </ul>	2004	
<ul> <li>Approval of first integrase inhibitor (raltegravir).         Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).     </li> <li>Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.         Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.         First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.     </li> <li>Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.         Treatment simplification and class sparing strategies addressed in randomized trials.     </li> <li>Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.</li> </ul>	2006	
Approval of first entry inhibitor, CCR5 co-receptor antagonist (maraviroc).  Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.		
<ul> <li>Approval of a new NNRTI (etravirine), and further evolution of 'salvage' therapy for patients with multiple failures.         Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.</li></ul>		
failures.  Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.	2008	
the use of combinations of at least two new fully active drugs.  First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.		
First description of the increase of non-AIDS-defining events in patients on long term anti-retroviral therapy.  Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.  Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.		Proof of concept of the possibility of obtaining durable HIV suppression in patients with multiple failures with
<ul> <li>Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and premature aging.         Treatment simplification and class sparing strategies addressed in randomized trials.     </li> <li>2010 Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.</li> </ul>		the use of combinations of at least two new fully active drugs.
premature aging. Treatment simplification and class sparing strategies addressed in randomized trials.  2010 Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.		
Treatment simplification and class sparing strategies addressed in randomized trials.  Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.	2009	Elucidation of the 'inflammatory' component of HIV disease and of its potential impact on co-morbidities and
Demonstration of the benefits of early initiation of anti-retroviral therapy, with subsequent modification of the international guidelines.		
international guidelines.	2012	
	2010	
2010 Demonstration that anti-rectioninal therapy is able to significantly reduce (11 v transmission).	2010	
	2010	Demonstration that anti-retrovital therapy is able to significantly reduce the variabilission.

proportion of retrieved publications were reviewed in this narrative. Selection of publications reviewed was not based on any particular criteria.

# Monitoring of ART

Of the eighty publications retrieved, 53 (66.25%) were on clinical use and monitoring of different ART regimens. The search for alternative to CD4 count as a biomarker of disease progress led to the study by Akanmu and others at Lagos in 2001<sup>5</sup>. The authors compared absolute lymphocyte count (ALC) and complete CD4 T-lymphocyte counts (CCC) as markers of disease progress before and during antiretroviral therapy. However, they concluded that ALC correlates weakly with CCC in patients undergoing anti-retroviral therapy and it may not serve as a perfect surrogate for CCC as a monitor of immunological response to therapy. This report was the first publication on ART on PUBMED using the search criteria described above. The use of ALC in Nigerians patients would have reduced the cost of investigations in our local population of patients but the study found that ALC was not as reliable as CCC. In 2006, Erhabor and others from Port Harcourt reported findings that showed that Absolute lymphocyte count could become a minimal inexpensive alternative to CD4 lymphocyte count in conjunction with WHO staging and clinical status of patient in determining the optimal time to initiate therapy particularly in resource limited settings where other expensive methods of CD4 enumeration are unavailable<sup>6</sup>. Thus, there is the need to gather more evidence in this area of research to answer the question of whether ALC and CD4 counts could be used interchangeably or to develop models that will make them interchangeable in our resource-limited setting.

## Adherence to ART

The effectiveness of any pharmacologic intervention depends on compliance to therapy. Researchers in Nigeria have worked considerably in the area of patient adherence to therapy. Iliasu and others from Kano were first to report that educational status of patients was the key factor that influenced compliance. They found that the better educated the patient is the better the compliance. However, the main reasons they identified for non-adherence to medications were nonavailability of drugs, forgetfulness, and lack of funds<sup>7</sup>. In 2008, Olowookere and others in a study done at Ibadan confirmed that there are problems with patient adherence to therapy in a study that showed that nonadherence to HAART is a significant problem in the ARV clinic and that the feeling of being healthy, forgetfulness, and unwillingness to disclose HIV status by people living with HIV AIDS (PLWHA) were significant barriers to adherence8. They recommended that efforts towards enhancing patients' adherence

should be made at ART clinics along the lines of the issues discovered. This recommendation is even more relevant today with the scale up of HAART in every region of the country.

## Highly Active Anti-Retroviral Therapy (HAART)

As described above, the HAART era started in 1996 following the publication of studies that showed the greatly enhanced efficacies of triple therapies in the management of HIV-AIDS. Ten years later, in 2006, Erhabor and others reported the benefits of HAART on a Nigerian population of people living with HIV-AIDS (PLWHA) from Port Harcourt. Their study showed that HAART significantly improved the immune and clinical status of the subjects studied9. Two years later, this finding was also confirmed by Olawumi and others at Ilorin<sup>10</sup>. In 2007, Chama from Maiduguri showed that a triple combination of nevirapine, stavudine and lamivudine in pregnancy significantly reduced mother-child transmission of the virus<sup>11</sup>. Also, in 2007, Idoko and others studied the use of various direct observation therapy of HAART treatment support modalities in Jos, Nigeria<sup>12</sup>. The study revealed that treatment outcomes were much better in the treatment-supported groups compared with the control self-therapy group. The paper concludes by strongly recommending the use of treatment support in the Nigerian settings. The most recent paper from the search, however, revealed findings that showed that Nigerian patients are already accumulating mutations associated with resistance to HAART. This information is very relevant to the continued success of the highly drug-dependent measures aimed at controlling the virus in Nigeria.

#### **CONCLUSION**

HIV-AIDS is a vibrant area of research in Nigeria. Although research here is highly driven by international ideas and publications, HIV scientists in Nigeria have produced a good number of very informative reports. Only a small proportion of the total number of publications retrieved by the PUBMED search could be reviewed in this historical narrative. The search criteria which were restricted to PUBMED and the publications selected and cited are limitations of this historical review.

In 2001 the African Summit on HIV/AIDS took place at Abuja, Nigeria. The UN General Assembly Special Session on AIDS resolved to scale up a comprehensive response involving prevention, treatment, care and support. At the summit Kofi Annan proposed the creation of a Global Fund to fight AIDS, Tuberculosis, and Malaria. This proposal led to increased funding of efforts at reducing the prevalence of the disease by providing free treatment for those living with the virus.

This has significantly and positively impacted on the epidemiology of the virus in Nigeria. However, HIV scientists in Nigeria need to develop original ideas with more forceful and beneficial local impact. There is also an urgent need to fund the training of our best brains by international collaborations and networks. Infrastructural development is also urgently required to enhance capacity for Basic and Molecular research upon which clinical research should be based and interpreted. Stronger policies towards non-pharmacologic interventions that will further drive down the incidence of the disease should be scaled up. While HIV-AIDS remains a significant challenge in Nigeria, our hope of overcoming this challenge remains the primary responsibility of every Nigerian.

## **ACKNOWLEDGEMENTS**

I wish to acknowledge the Managers of PUBMED (the United States National Library of Medicine, NIH), who have continued to make this very important database freely available to all. I acknowledge my wife whose continued support and contributions have always improved the contents of the chronicles of medical history. I thank God for the inspiration and motivation to write this historical review on ART use in Nigeria.

## REFERENCES

- 1. **Vella S,** Schwartlander B, Sow SP, *et al.* The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. *Aids* 2012, 26:1231-1241.
- 2. **Palmisano L,** Vella S: A brief history of antiretroviral therapy of HIV infection: success and challenges. *Ann Ist Super Sanita* 2011, 47:44-48.
- Hammer SM, Katzenstein DA, Hughes MD, et al: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996, 335:1081-1090.
- 4. **Hammer SM,** Squires KE, Hughes MD, *et al:* A controlled trial of two nucleoside analogues plus indinavir in persons with human immuno-

- deficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. *N Engl J Med* 1997, 337:725-733.
- 5. **Akanmu AS,** Akinsete I, Eshofonie AO, *et al:* Absolute lymphocyte count as surrogate for CD4+ cell count in monitoring response to antiretroviral therapy. *Niger Postgrad Med J* 2001, 8:105-111.
- 6. **Erhabor O,** Uko EK, Adias T: Absolute lymphocyte count as a marker for CD4 T-lymphocyte count: criterion for initiating antiretroviral therapy in HIV infected Nigerians. *Niger J Med* 2006, 15:56-59.
- 7. **Iliyasu Z,** Kabir M, Abubakar IS, *et al:* Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching Hospital, Kano, Nigeria. *Niger J Med* 2005, 14:290-294.
- 3. **Olowookere SA,** Fatiregun AA, Akinyemi JO, *et al:* Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV/AIDS in Ibadan, Nigeria. *J Infect Dev Ctries* 2008, 2:369-372.
- 9. **Erhabor O,** Ejele OA, Nwauche CA: The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience. *Niger J Clin Pract* 2006, 9:128-133.
- Olawumi HO, Olatunji PO, Salami AK, et al: Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin. Niger J Clin Pract 2008, 11:312-315.
- 11. **Chama C,** Gashau W, Oguche S: The value of highly active antiretroviral therapy in the prevention of mother-to-child transmission of HIV. *J Obstet Gynaecol* 2007, 27:134-137.
- 12. **Idoko JA,** Agbaji O, Agaba P, *et al:* Direct observation therapy-highly active antiretroviral therapy in a resource-limited setting: the use of community treatment support can be effective. *Int J STD AIDS* 2007, 18:760-763